Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Conjugate or complex
Patent
1996-09-30
1999-03-02
Achutamurthy, Ponnathapura
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Conjugate or complex
4241301, 4241751, 4241941, 546129, 546130, 546131, 546132, 5462794, 514343, 530405, 530409, A61K 39385, A61K 39395, C07D45102
Patent
active
058767274
ABSTRACT:
Hapten-carrier conjugates capable of eliciting anti-hapten antibodies in vivo are disclosed. Methods of preparing the hapten-carrier conjugates and therapeutic compositions are also disclosed. Where the hapten is a drug of abuse, a therapeutic composition containing the hapten-carrier conjugate is particularly useful in the treatment of drug addiction, more particularly, cocaine addiction. Passive immunization using antibodies raised against conjugates of the instant invention is also disclosed. The therapeutic composition is suitable for co-therapy with other conventional drugs.
REFERENCES:
patent: 4045420 (1977-08-01), Soffer et al.
patent: 4375414 (1983-03-01), Strahilevitz
patent: 5229490 (1993-07-01), Tam
patent: 5256066 (1993-10-01), Blincko
patent: 5283066 (1994-02-01), Liu et al.
Wu et al., Vaccine., vol. 12., No. 3., pp. 215-222. 1994.
Kovalev et al. (1979) Khim. Farm. (USSR) pp. 615-618 with translation.
Harless et al. Abstract: Active Immunization Prevents Analgesic and Reinforcing Effects of Cocaine, Twenty-Fourth Annual Western Psychology Conference, Apr. 1995.
Wainer et al. (1972) Science 176:1143-1145.
Wainer et al. (1972) Science 178:647-648.
Spector et al. (1970) Science 168:1347-1348.
Wainer et al. (1973) The Journal of Immunology 110:667-673.
Van Vunakis et al. (1972) The Journal of Pharmacology and Experimental Therapeutics 180:514-521.
Spector (1971) The Journal of Pharmacology and Experimental Therapeutics 178:253-258.
Castro et al. (1980) Eur. J. Biochem 104:331-340.
Castro et al. (1975) Biochemical and Biophysical Research Communications 67:583-589.
Matsushita et al. (1974) Biochemical and Biophysical Research Communications 57:1006-1010.
Castro et al. (1985) Biochemical Archives 1:173-183.
Castro et al. (1986) Biochemical Communications in Chemical Pathology and Pharmacology 51:393-404.
Decato et al. (1977) Journal of Immunological Methods 18:201-213.
Killian et al. (1978) Pharmacology Biochemistry & Behavior 9:347-352.
Berkowitz (1972) Science 178:1290-1292.
Berkowitz et al. (1975) Life Sciences 15:1017-1028.
Zimmermann et al. (1976) Proc. West. Pharmacol. Soc. 19:260-265.
Spector et al. (1973) Pharmacological Reviews 25:281-291.
Spector (1976) Biochemical Pharmacology 25:2427-2428.
Lomax et al. (1973) Proc. West. Pharmacol. Soc. 16:252-256.
Wainer et al. (1973) Nature 241:537-538.
Miller et al. (1974) Proc. West. Pharmacol. Soc. 17:69-72.
Herndon (1975) Life Sciences 17:151-158.
Schmidt et al. (1971) The Journal of Clinical Investigation 50:866-871.
Colburn (1980) Drug Method Rev. 11:223-262.
Pentel et al. (1991) Drug Meth. & Disp. 19:24-28.
Kovalev et al. (1980) Khim. Pharm. pp. 200-204.
Exley Mark A.
Fox Barbara S.
Gefter Malcolm L.
Greenstein Julia L.
Powers Stephen P.
Achutamurthy Ponnathapura
Immulogic Pharmaceutical Corporation
Ponnalun P.
LandOfFree
Hapten-carrier conjugates for use in drug-abuse therapy and meth does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hapten-carrier conjugates for use in drug-abuse therapy and meth, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hapten-carrier conjugates for use in drug-abuse therapy and meth will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-419808